SUSTAIN-6
2016
Trial to Evaluate CV and Other Long-term Outcomes with Semaglutide
In 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.
Result
Efficacy: 3-point MACEHR 0.74 · P = 0.02
Safety: Retinopathy complicationsHR 1.76 · P = 0.02
Below 1 favours subcutaneous semaglutide 0.5 or 1.0 mg weekly, above 1 favours placebo.
Event rates Subcutaneous semaglutide 0.5 or 1.0 mg weekly 6.6% vs placebo 8.9% (3-point MACE)
Also reported: Non-fatal stroke −39 %.
- Subtopic
- CV outcome trial
- Design
- Double-blind RCT, median 2.1 yr
- Relevance
- Important: one of several pillars.
- Also listed in
- Diabetes & cardiometabolic
- Source
- Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.doi 10.1056/NEJMoa1607141
Discussion & critique
Confirmed the GLP-1 RA class effect on MACE; the retinopathy signal remains debated and probably reflects rapid glycaemic improvement.